Proposed Data Collection Submitted for Public Comment and Recommendations, 67942 [2019-26692]
Download as PDF
<![CDATA[
67942
Federal Register / Vol. 84, No. 239 / Thursday, December 12, 2019 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Final Effect of Designation of a Class
of Employees for Addition to the
Special Exposure Cohort
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period;
Withdrawal.
AGENCY:
Notice.
HHS gives notice concerning
the final effect of the HHS decision to
designate a class of employees from the
West Valley Demonstration Project in
West Valley, New York, as an addition
to the Special Exposure Cohort (SEC)
under the Energy Employees
Occupational Illness Compensation
Program Act of 2000.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Grady Calhoun, Director, Division of
Compensation Analysis and Support,
NIOSH, 1090 Tusculum Avenue, MS C–
46, Cincinnati, OH 45226–1938,
Telephone 513–533–6800. Information
requests can also be submitted by email
to DCAS@CDC.GOV.
On
October 25, 2019, as provided for under
42 U.S.C. 7384l(14)(C), the Secretary of
HHS designated the following class of
employees as an addition to the SEC:
SUPPLEMENTARY INFORMATION:
All Atomic Weapons Employees who
worked at the West Valley Demonstration
Project in West Valley, New York, during the
period from January 1, 1969, through
December 31, 1973, for a number of work
days aggregating at least 250 work days,
occurring either solely under this
employment or in combination with work
days within the parameters established for
one or more other classes of employees in the
Special Exposure Cohort.
This designation became effective on
November 24, 2019. Therefore,
beginning on November 24, 2019,
members of this class of employees,
defined as reported in this notice,
became members of the SEC.
khammond on DSKJM1Z7X2PROD with NOTICES
[60Day–20–0020; Docket No. CDC–2019–
0109]
Authority: 42 U.S.C. 7384q(b). 42 U.S.C.
7384l(14)(C).
John J. Howard,
Director, National Institute for Occupational
Safety and Health.
The Centers for Disease
Control and Prevention (CDC) in the
Department of Health and Human
Services (HHS) announces the
withdrawal of the notice published
under the same title on December 6,
2019 for public comment.
DATES: December 12, 2019.
FOR FURTHER INFORMATION CONTACT:
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: On
December 6, 2019 CDC published a
notice in the Federal Register titled
‘‘Proposed Data Collection Submitted
for Public Comment and
Recommendations’’ (84 FR 66902). This
notice with Federal Register Document
2019–26370 and Docket number CDC–
2019–0109, was published prematurely
and inadvertently. The notice is being
withdrawn immediately for public
comment. A new notice will be
published at a later date for public
comment.
SUMMARY:
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2019–26692 Filed 12–11–19; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–E–2529]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; BRIVIACT ORAL
SOLUTION, New Drug Application
205838
[FR Doc. 2019–26747 Filed 12–11–19; 8:45 am]
AGENCY:
BILLING CODE 4163–18–P
HHS.
VerDate Sep<11>2014
17:56 Dec 11, 2019
Jkt 250001
PO 00000
Food and Drug Administration,
Frm 00032
Fmt 4703
Sfmt 4703
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for BRIVIACT ORAL SOLUTION and is
publishing this notice of that
determination as required by law. FDA
has made the determination because of
the submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
DATES: Anyone with knowledge that any
of the dates as published (see the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by February 10, 2020.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
June 9, 2020. See ‘‘Petitions’’ in the
SUPPLEMENTARY INFORMATION section for
more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before February 10,
2020. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of February 10, 2020.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
E:\FR\FM\12DEN1.SGM
12DEN1
]]>Agencies
[Federal Register Volume 84, Number 239 (Thursday, December 12, 2019)]
[Notices]
[Page 67942]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26692]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-20-0020; Docket No. CDC-2019-0109]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period; Withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) in the
Department of Health and Human Services (HHS) announces the withdrawal
of the notice published under the same title on December 6, 2019 for
public comment.
DATES: December 12, 2019.
FOR FURTHER INFORMATION CONTACT: Information Collection Review Office,
Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS-
D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: [email protected].
SUPPLEMENTARY INFORMATION: On December 6, 2019 CDC published a notice
in the Federal Register titled ``Proposed Data Collection Submitted for
Public Comment and Recommendations'' (84 FR 66902). This notice with
Federal Register Document 2019-26370 and Docket number CDC-2019-0109,
was published prematurely and inadvertently. The notice is being
withdrawn immediately for public comment. A new notice will be
published at a later date for public comment.
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2019-26692 Filed 12-11-19; 8:45 am]
BILLING CODE 4163-18-P
